* TRACON Pharmaceuticals Inc TCON.OQ TCON.O is expected
to show no change in quarterly revenue when it reports
results on November 14.
*
* Refinitiv's mean analyst estimate for TRACON
Pharmaceuticals
Inc is for a loss of 28 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for TRACON
Pharmaceuticals Inc is $9, above its last closing price
of $1.55.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.36 -0.37 -0.31 Beat 16.8
Mar. 31 2022 -0.42 -0.42 -0.48 Missed -15
Dec. 31 2021 -0.36 -0.35 -0.40 Missed -13.4
Sep. 30 2021 -0.32 -0.32 -0.38 Missed -17.2
Jun. -0.32 -0.31 -0.58 Missed -86.2
30 2021
Mar. 31 2021 -0.30 -0.30 -0.33 Missed -8.2
Dec. 31 2020 -0.44 -0.41 -0.31 Beat 23.6
Sep. 30 2020 -0.64 -0.65 -0.38 Beat 41.5
This summary was machine generated November 12 at 02:59 GMT.
All figures in US dollars unless otherwise stated